Analysts expect Sionna Therapeutics to report a Q3 2026 EPS of -$0.62 on zero revenue, with the current stock price of $4.01 trading significantly below the $20.86 average analyst target.
Investors are laser-focused on the company's cash runway and strategic reorganization following the catastrophic Phase 2a clinical failure of its lead cystic fibrosis candidate, SION-719, in August.
The 90% stock collapse has forced management to pivot focus toward the SION-451 and SION-2222 dual-combination programs. Markets are seeking clarity on the timeline for the upcoming AscenSION CF trial and the sustainability of the company's $283 million asset base.